Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly

Neurobiology of Aging

Volumn 33, Issue 7, 2012, Pages 1215-1227

  Glodzik, Lidia ^a   Mosconi, Lisa ^a   Tsui, Wai ^a,b   de Santi, Susan ^a,c   Zinkowski, Raymond ^d   Pirraglia, Elizabeth ^a   Rich, Kenneth E ^a   McHugh, Pauline ^a   Li, Yi ^a   Williams, Schantel ^a   Ali, Fahad ^a   Zetterberg, Henrik ^e   Blennow, Kaj ^e   Mehta, Pankaj ^f   de Leon, Mony J ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c BAYER CORPORATION   (United States)

^d Applied NeuroSolutions Inc   (United States)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Aging; Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Hypertension; MRI

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRIEF COGNITIVE RATING SCALE; CAUDATE NUCLEUS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBELLUM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ASSESSMENT; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FRONTAL CORTEX; GLOBAL DETERIORATION SCALE; GRAY MATTER; GRAY MATTER INJURY; HUMAN; HYPERTENSION; IMAGE ANALYSIS; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MEDIAL TEMPORAL LOBE; MESENCEPHALON; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PRECUNEUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TEMPORAL LOBE; THALAMUS; VOXEL BASED MORPHOMETRY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; ATROPHY; BIOLOGICAL MARKERS; CEREBRAL CORTEX; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 84861198126     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.02.012     Document Type: Article

References (57)

1. Ashburner J., Friston K.J. Voxel-based morphometry--the methods. Neuroimage 2000, 11:805-821.
2. Ashburner J., Friston K.J. Imaging techniques: Voxel based morphometry. The Encyclopedia of Neuroscience 2009, 471-477. Elsevier, New York. L.R. Squire (Ed.).
3. Bech P., Kastrup M., Rafaelsen O.J. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr. Scand. Suppl. 1986, 326:1-37.
4. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's Disease. Lancet Neurol. 2006, 368:387-403.
5. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in alzheimer disease?. Mol. Chem. Neuropathol. 1995, 26:231-245.
6. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
7. Brys M., Glodzik-Sobanska L., Switalski R., Rich K., Pirraglia E., Mosconi L., De Santi S., Javier E., Mehta P., Zinkowski R., Pratico D., Wallin A., Blennow K., Sadowski M., Rusinek H., de Leon M.J. MRI improves CSF biomarkers in the early detection of Alzheimer's Disease. J. Alzheimers Dis. 2008, 16:351-362.
8. Buerger K., Zinkowski R., Teipel S.J., Arai H., DeBernardis J., Kerkman D., McCulloch C., Padberg F., Faltraco F., Goernitz A., Tapiola T., Rapoport S.I., Pirttila T., Moller H.J., Hampel H. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am. J. Psychiatry 2003, 160:376-379.
9. Cervos-Navarro J., Diemer N.H. Selective vulnerability in brain hypoxia. Crit. Rev. Neurobiol. 1991, 6:149-182.
10. Chetelat G., Villemagne V.L., Bourgeat P., Pike K.E., Jones G., Ames D., Ellis K.A., Szoeke C., Martins R.N., O'Keefe G.J., Salvado O., Masters C.L., Rowe C.C. Relationship between atrophy and beta -amyloid deposition in Alzheimer Disease. Ann. Neurol. 2010, 67:317-324. Australian Imaging Biomarkers and Lifestyle Research Group.
11. Chobonian A., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., Jones D.W., Matterson B.J., Oparil S., Wright J.T., Rocella E.J. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003, 289:2560-2572.
12. de Leon M.J., George A.E., Stylopoulos A., Smith G., Miller D.C. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet 1989, 2:672-673.
13. den Heijer T., Launer L.J., Prins N.D., van Dijk E.J., Vermeer S.E., Hofman A., Koudstaal P.J., Breteler M.M. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurologist 2005, 64:263-267.
14. Driscoll I., Zhou Y., An Y., Sojkova J., Davatzikos C., Kraut M.A., Ye W., Ferrucci L., Mathis C.A., Klunk W.E., Wong D.F., Resnick S.M. Lack of association between (11)C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiol. Aging. 2010, 10.1016/j.neurobiolaging.2009.12.008.
15. Fagan A.M., Head D., Shah A.R., Marcus D., Mintun M., Morris J.C., Holtzman D.M. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 2009, 65:176-183.
16. Fagan A.M., Mintun M.A., Mach R.H., Lee S., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
17. Fagan A.M., Roe C.M., Xiong C., Mintun M., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007, 64:343-349.
18. Fazekas F., Chawluk J.B., Alavi A., Hurtig H.I., Zimmerman R.A. MR Signal Abnormalities at 1.5 T in Alzheimer's Dementia and Normal Aging. AJR Am. J. Roentgenol. 1987, 149:351-356.
19. Fennnema-Notestine C., Hagler D.J.J., McEvoy L.K., Fleisher A.S., Wu E.H., Karow D.S., Dale A.M. Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum. Brain Mapp. 2009, 30:3238-3253. Alzheimer's Disease Neuroimaging Initiative.
20. Firbank M.J., Wiseman R.M., Burton E.J., Saxby B.K., O'Brien J.T., Ford G.A. Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. Brain atrophy, WMH change and blood pressure. J. Neurol. 2007, 254:713-721.
21. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
22. Freeborough P.A., Woods R.P., Fox N.C. Accurate registration of serial 3d mr brain images and its application to visualizing change in neurodegenerative disorders. J. Comput. Assist. Tomogr. 1996, 20:1012-1022.
23. Gianaros P.J., Greer P.J., Ryan C.M., Jennings J.R. Higher blood pressure predicts lower regional grey matter volume: consequences on short-term information processing. Neuroimage 2006, 31:754-765.
24. Gilbert J.G., Levee R.F., Catalano F.L. A preliminary report on a new memory scale. Percept. Mot. Skills 1968, 27:277-278.
25. Glodzik L., De Santi S., Tsui W.H., Mosconi L., Zinkowski R., Pirraglia E., Wang H., Li Y., Rich K.E., Zetterberg H., Blennow K., Mehta P., de Leon M.J. Phosphorylated Tau231, memory decline and medial temporal atrophy in normal elders. Neurobiol. Aging 2010, 10.1016/j.neurobiolaging.2009.12.026.
26. Glodzik-Sobanska L., Rusinek H., Mosconi L., Li Y., Zhan J., De Santi S., Convit A., Rich K.E., Brys M., de Leon M. The role of quantitative structural imaging in the early diagnosis of Alzheimer's Disease. Neuroimaging Clin. N. Am. 2005, 15:803-826.
27. Godin O., Maillard P., Crivello F., Alperovitch A., Mazoyer B., Tzourio C., Dufouil C. Association of white-matter lesions with brain atrophy markers: the three-city Dijon MRI study. Cerebrovasc. Dis. 2009, 28:177-184.
28. Good C.D., Scahill R.I., Fox N.C., Ashburner J., Friston K.J., Chan D., Crum W.R., Rossor M.N., Frackowiak R.S.J. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage 2002, 17:29-46.
29. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between csf biomarkers and incipient alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006, 5:228-234.
30. Josephs K.A., Whitwell J.L., Ahmed Z., Shiung M.M., Weigand S.D., Knopman D.S., Boeve B.F., Parisi J.E., Petersen R.C., Dickson D.W., Jack C.R. Beta-amyloid burden is not associated with rates of brain atrophy. Ann. Neurol. 2008, 63:204-212.
31. Klunk W.E., Price J.C., Mathis C.A., Tsopelas N.D., Lopresti B.J., Ziolko S.K., Bi W., Hoge J.A., Cohen A.D., Ikonomivic M.D., Saxton J.A., Snitz B.E., Pollen D.A., Moonis M., Lippa C.F., Swearer J.M., Johnson K.A., Rentz D.M., Fischman A.J., Aizenstein H.J., DeKosky S.T. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. 2007, 27:6174-6184.
32. Kohnken R., Buerger K., Zinkowski R., Miller C., Kerkman D., DeBernardis J., Shen J., Moller H.J., Davies P., Hampel H. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 2000, 287:187-190.
33. Koivunen J., Verkkoniemi A., Aalto S., Paetau A., Ahonen J.-P., Viitanen M., Negren K., Rokka J., Haaparanta M., Kalimo H., Rinne J.O. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 2008, 131:1845-1853.
34. Korf E.S.C., White L.R., Scheltens P., Launer L.J. Midlife blood pressure and the risk of hippocampal atrophy: The Honolulu Asia Aging Study. Hypertension 2004, 44:29-34.
35. Lancaster J.L., Woldorff M.G., Parsons L.M., Liotti M., Freitas C.S., Rainey L., Kochunov P.V., Nickerson D., Mikiten S.A., Fox N.C. Automated Talairach atlas labels for functional brain mapping. Hum. Brain Mapp. 2000, 10:120-131.
36. Lewczuk P., Esselmann H., Otto M., Maler J.M., Henkel A.W., Henkel M.K., Eikenberg O., Antz C., Krause W.R., Reulbach U. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol. Aging 2004, 25:273-281.
37. Li G., Sokal I., Quinn J.F., Leverenz B., Brodey M., Schellenberg G.D., Kaye J.A., Raskind M.A., Zhang J., Peskind E.R., Montine T.J. CSF Tau/A{Beta}42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurologist 2007, 69:631-639.
38. Li Y., Rinne J.O., Mosconi L., Pirraglia E., Rusinek H., De Santi S., Kemppainen N., Nagren K., Kim B.C., Tsui W., de Leon M.J. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2169-2181.
39. Loew A.D., Yanowsky I., Parikshak N., Hua X., Lee S., Toga A.W., Jack C.R.J., Bernstein M.A., Briston P.J., Gunter J.L., Ward C.P., Borowski B.J., Shaw L.M., Trojanowski J.Q., Fleisher A.S., Harvey D., Kornak J., Schuff N., Alexander G.E., Weiner M.W., Thompson P.M. Alzheimer's Disease Neuroimaging Initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 2009, 45:645-655. Alzheimer's Disease Neuroimaging Initiative.
40. Luoto T., Haikonen S., Haapasalo H., Goebeler S., Huhtala H., Erkinjunti T., Karhunen P.J. Large vessel cerebral atherosclerosis is not in direct association with neuropathological lesions of Alzheimer's disease. Eur. Neurol. 2009, 62:93-98.
41. Metha P.D., Pirttila T., Metha S.P., Sersen E., Aisen P.S., Wisnewski H.M. Plasma and cerebrospinal fluids levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer's Disease. Arch. Neurol. 2000, 57:100-105.
42. Mosconi L. Brain Glucose Metabolism in the Early and Specific Diagnosis of Alzheimer's Disease. Eur. J. Nucl. Med. 2005, 32:486-510.
43. Mosconi L., Rinne J.O., Tsui W.H., Berti V., Li Y., Wang H., Murray J., Scheini N., Någren K., Williams S., Glodzik L., De Santia S., Vallabhajosula S., de Leon M.J. Increased fibrillar amyloid-β burden in normal individuals with a family history of late onset Alzheimer's. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:5949-5954.
44. Nagai M., Hoshide S., Ishikawa J., Shimada K., Kario K. Ambulatory blood pressure as an independent determinant of brain atrophy and cognitive function in elderly hypertension. J. Hypertens. 2008, 26:1636-1641.
45. Pennanen C., Testa C., Laakso M.P., Hallikainen M., Helkala E.-L., Haninen T., Kivipelto M., Kononen M., Nissinen A., Tervo S., Vanhanen M., Vanninen R., Frisoni G.B., Soininen H. A Voxel based morphometry study on mild cognitive impairment. J. Neurol. Neurosurg. Psychiatry 2005, 76:11-14.
46. Petrie E.C., Cross D.J., Galasko D., Schellenberg G.D., Raskind M.A., Peskind E.R., Minoshima S. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch. Neurol. 2009, 66:632-637.
47. Petrovitch H., White L.R., Izmirilian G., Ross G.W., Havlik R.J., Markesbery W.R., Nelson J., Davis D.G., Hardman J., Foley D.J., Launer L.J. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol. Aging 2000, 21:57-62.
48. Reisberg B., Ferris S.H. The Brief Cognitive Rating Scale (BCRS). Psychopharmacology (Berl). Bull. 1988, 24:629-636.
49. Reisberg B., Sclan S.G., Franssen E.H., de Leon M.J., Kluger A., Torossian C.L., Shulman E., Steinberg G., Monteiro I., McRae T., Boksay I., Mackell J.A., Ferris S.H. Clinical stages of normal aging and Alzheimer's disease: the GDS Staging System. Neurosci. Res. Commun. 1993, 13(suppl 1):551-554.
50. Schöll M., Almkvist O., Axelman K., Stefanova E., Wall A., Westman E., Långström B., Lannfelt L., Graff C., Nordberg A. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol. Aging 2009, 10.1016/j.neurobiolaging.2009.08.016.
51. Sluimer J., Bouwman F.H., Vrenken H., Blankenstein M.A., Barkhof F., van der Flier W.M., Scheltens P. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol. Aging 2010, 31:492-498.
52. Sparks D.L., Scheff S.W., Liu H., Landers T.M., Coyne C.M., Hunsaker J.C.I. Increased incidence of neurofibrillary tangles (nft) in non-demented individuals with hypertension. J. Neurol. Sci. 1995, 131:162-169.
53. Strassburger T.L., Lee H.C., Daly E.M., Szczepanik J., Krasuski J.S., Mentis M.J., Salerno J.A., DeCarli C., Schapiro M.B., Alexander G.E. Interactive effects of age and hypertension on volumes of brain structures. Stroke 1997, 28:1410-1417.
54. Talairach J., Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain 1988, Stuttgart, Thieme.
55. Wang L., Larson E.B., Sonnen J.A., Shofer J.B., McCormick W., Bowen J.D., Montine T.J., Li G. Blood pressure and brain injury in older adults: findings from a community-based autopsy study. J. Am. Geriatr. Soc. 2009, 57:1975-1981.
56. Wechsler D. WAIS-R Manual 1981, Psychological Corporation, New York.
57. Wiltfang J., Esselmann H., Bibl M., Hull M., Hampel H., Kessler H., Frolich L., Schroder J., Peters O., Jessen F., Luckhaus C., Perneczky R., Jahn H., Fiszer M., Maler J.M., Zimmermann R., Bruckmoser R., Kornhuber J., Lewczuk P. Amyloid Beta peptide ratio 42/40 but not A Beta 42 correlates with phospho-tau in patients with low- and high-CSF A Beta 40 load. J. Neurochem. 2007, 101:1053-1059.